Mylene Sejalon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mylene Sejalon has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Clarence Charnay
ICGM, University of Montpellier, UMR-CNRS 5253, 34293 Montpellier, France
1 shared publication - Dina Aggad
Institut des Biomolécules Max Mousseron, UMR 5247 CNRS, UM-Faculté de Pharmacie, 15 Avenue Charles Flahault, CEDEX 5, 34093 Montpellier, France
1 shared publication - Eric Vivès
PhyMedExp, University of Montpellier, INSERM, CNRS, 34295 Montpellier, France
1 shared publication - Jean-Olivier Durand
ICGM, University of Montpellier, CNRS, ENSCM, Montpellier, France
1 shared publication - Jelena Budimir
Georg-Augus-University Goettingen
1 shared publication - Laure Lichon
IBMM, University Montpellier, CNRS, ENSCM, 34193 Montpellier, France
1 shared publication
Latest Publications
- Open Access
Large Pore Mesoporous Silica and Organosilica Nanoparticles for Pepstatin A Delivery in Breast Cancer Cells
(1) Background: Nanomedicine has recently emerged as a new area of research, particularly to fight cancer. In this field, we were interested in the vectorization of pepstatin A, a peptide which does not cross cell membranes, but which is a potent inhibitor of cathepsin D, an aspartic protease particularly overexpressed in breast cancer. (2) Methods: We studied two kinds of nanoparticles. For pepstatin A delivery, mesoporous silica nanoparticles with large pores (LPMSNs) and hollow organosilica nanoparticles (HOSNPs) obtained through the sol–gel procedure were used. The nanoparticles were loaded with pepstatin A, and then the nanoparticles were incubated with cancer cells. (3) Results: LPMSNs were monodisperse with 100 nm diameter. HOSNPs were more polydisperse with diameters below 100 nm. Good loading capacities were obtained for both types of nanoparticles. The nanoparticles were endocytosed in cancer cells, and HOSNPs led to the best results for cancer cell killing. (4) Conclusions: Mesoporous silica-based nanoparticles with large pores or cavities are promising for nanomedicine applications with peptides.
Open AccessLarge Pore Mesoporous Silica and Organosilica Nanoparticles for Pepstatin A Delivery in Breast Cancer Cells
(1) Background: Nanomedicine has recently emerged as a new area of research, particularly to fight cancer. In this field, we were interested in the vectorization of pepstatin A, a peptide which does not cross cell membranes, but which is a potent inhibitor of cathepsin D, an aspartic protease particularly overexpressed in breast cancer. (2) Methods: We studied two kinds of nanoparticles. For pepstatin A delivery, mesoporous silica nanoparticles with large pores (LPMSNs) and hollow organosilica nanoparticles (HOSNPs) obtained through the sol–gel procedure were used. The nanoparticles were loaded with pepstatin A, and then the nanoparticles were incubated with cancer cells. (3) Results: LPMSNs were monodisperse with 100 nm diameter. HOSNPs were more polydisperse with diameters below 100 nm. Good loading capacities were obtained for both types of nanoparticles. The nanoparticles were endocytosed in cancer cells, and HOSNPs led to the best results for cancer cell killing. (4) Conclusions: Mesoporous silica-based nanoparticles with large pores or cavities are promising for nanomedicine applications with peptides.